论文部分内容阅读
目的研究乳腺癌原发肿瘤切除前后的血清MMP-9的水平及动态变化规律,为临床治疗提供可靠依据。方法选取医院普外科经病理切片证实的乳腺癌患者100例,分别监测100例乳腺癌患者术前、术后第1、7、14天血清MMP-9的浓度,40例乳腺良性肿瘤手术患者作为对照组,30例健康志愿者确定血清MMP-9水平;结果乳腺癌患者术前血清MMP-9浓度显著高于乳腺良性肿瘤患者术前及健康人血清水平(P<0.01);手术切除肿瘤后,术后第1天乳腺癌患者的血清MMP-9水平显著升高(313.67±60.43ng/m L),术后第7、14天逐渐降低(197.56±56.31ng/ml、141.77±32.67ng/m L)(P<0.05)。结论乳腺癌患者血清MMP-9水平显著高于乳腺良性肿瘤患者及健康人,原发肿瘤切除后血清MMP-9水平显著下降。
Objective To study the levels and dynamic changes of serum MMP-9 levels before and after resection of primary breast cancer and provide a reliable basis for clinical treatment. Methods 100 cases of breast cancer confirmed by pathology biopsy in hospital were selected. Serum MMP-9 levels in 100 cases of breast cancer patients before and after operation were monitored respectively. Forty patients with breast benign tumor were treated with The levels of serum MMP-9 in breast cancer patients were significantly higher than those in benign breast tumors (P <0.01) The level of serum MMP-9 in breast cancer patients was significantly higher on the first postoperative day (313.67 ± 60.43ng / m L) and gradually decreased on the 7th and 14th postoperative day (197.56 ± 56.31ng / ml, 141.77 ± 32.67ng / m L) (P <0.05). Conclusion The serum level of MMP-9 in patients with breast cancer is significantly higher than that in patients with benign breast tumors and healthy people. The level of serum MMP-9 after primary resection is significantly decreased.